PMC7520673_01
Spirogram before initiation of omalizumab.
CRIPU2020-8898454.001.jpg
PMC7520673_01_CRIPU2020-8898454.001.jpg
fig1
Her spirometry (Figure 1) showed persistent obstructive ventilatory defect (postbronchodilator FEV1 74% predicted).
Exacerbations needing escalation of steroid use before and after initiation of anti-IgE treatment.
CRIPU2020-8898454.002.jpg
PMC7520673_01_CRIPU2020-8898454.002.jpg
fig2
She had only 2 exacerbations needing hiking up of steroids during these nine months of therapy as opposed to 7 in the 6 months prior to omalizumab initiation (Figure 2).